GALECTIN THERAPEUTICS INC (GALT) Stock Fundamental Analysis

Name: GALECTIN THERAPEUTICS INC (GALT) Stock
Brand: GALECTIN THERAPEUTICS INC
Rating: 4 (3 reviews)

USA • Nasdaq • NASDAQ:GALT • US3632252025

2.83 USD

-0.1 (-3.41%)

Last: Jan 30, 2026, 08:00 PM

Fundamental Rating

We assign a fundamental rating of 0 out of 10 to GALT. GALT was compared to 525 industry peers in the Biotechnology industry. GALT has a bad profitability rating. Also its financial health evaluation is rather negative. GALT has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GALT has reported negative net income.
In the past year GALT has reported a negative cash flow from operations.
GALT had negative earnings in each of the past 5 years.
GALT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -291.04%, GALT is not doing good in the industry: 91.05% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-291.04%
ROE	N/A
ROIC	N/A

ROA(3y)-203.75%

ROA(5y)-152.87%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GALT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GALT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GALT has more shares outstanding
Compared to 1 year ago, GALT has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -64.65, we must say that GALT is in the distress zone and has some risk of bankruptcy.
GALT's Altman-Z score of -64.65 is on the low side compared to the rest of the industry. GALT is outperformed by 91.81% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-64.65

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

GALT has a Current Ratio of 0.09. This is a bad value and indicates that GALT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.09, GALT is not doing good in the industry: 94.29% of the companies in the same industry are doing better.
A Quick Ratio of 0.09 indicates that GALT may have some problems paying its short term obligations.
The Quick ratio of GALT (0.09) is worse than 94.29% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.09
Quick Ratio	0.09

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.18% over the past year.

EPS 1Y (TTM)19.18%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%27.78%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GALT will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.76% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y34.24%

EPS Next 2Y20.41%

EPS Next 3Y11.76%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GALT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GALT. No positive earnings are expected for the next year.